CTOs on the Move

Zenflow

www.zenflow.com

 
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). Millions of patients do not see effective relief from drugs, yet decline to undergo an invasive surgical procedure with high risk of side effects such as sexual dysfunction.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.zenflow.com
  • 395 Oyster Point Blvd Suite 501
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Zenflow raised $24.3M on 04/15/2021

Similar Companies

Ivek

Ivek Corp. is a North Springfield, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIOCARDIA

BIOCARDIA is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Delta Medical Systems Inc

Delta Medical Systems Inc is a Pewaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bacterin

Bacterin is an accredited tissue bank and medical device company that designs, processes, manufactures, and markets advanced medical products. Using designs focused on efficacy and safety for the patient, and functionality and ease of use for the surgeon, our innovative products fulfill niche needs in the industry.   It is important that you know and trust your allograft provider.  We are a specialty tissue bank focused on processing and distributing quality, cost-effective allografts to you and your patients.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.